Compare

Glutathione vs Semaglutide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Glutathione

94 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 59% · Mixed 23% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-167
Focus
-146
Sleep quality
-166
Lean mass
-33
Joint comfort
6

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-71
Nausea
-66
Water retention
-21
Appetite loss
-38
Injection site reaction
5

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–3 mg

0.05–0.1 mg
2
0.1–0.2 mg
9
0.2–0.4 mg
12
0.4–0.6 mg
21
0.6–1 mg
11
1–2 mg
2
2–3 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing18stacking16side effects24glutathione27

How repeat users are trending

Among repeat reporters, 53% said they felt similar to their last entry, 32% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 21 repeat reporters

Semaglutide

304 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 58% · Mixed 30% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
67
Recovery
108
Digestive comfort
159
Skin appearance
165
Appetite control
76

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
163
Anxiety
188
Flushing
124
Headache
161
GI discomfort
75

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
4
50–100
14
100–200
18
200–400
9
400–600
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing28stacking16side effects24semaglutide12

How repeat users are trending

Among repeat reporters, 53% said they felt similar to their last entry, 44% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 67 repeat reporters

Sources (16)

Published sources linked on the Glutathione and Semaglutide wiki pages.

  1. PubMed

    Randomized controlled trial of oral glutathione supplementation on body stores of glutathione

    Richie JP Jr, Nichenametla S, Neidig W, et al. Eur J Nutr. 2015

    Source
    Wiki study page →
  2. PubMed

    Intravenous glutathione for skin lightening: Inadequate safety data

    Davids LM, van Wyk JC, Khumalo NP. S Afr Med J. 2016

    Source
    Wiki study page →
  3. PubMed

    Dietary glutathione supplementation enhances antioxidant activity and protects against lipopolysaccharide-induced acute hepatopancreatic injury and cell apoptosis in Chinese mitten crab, Eriocheir sinensis

    Liu JD, Liu WB, Zhang CY, et al. Fish & shellfish immunology. 2020

    Source
    Wiki study page →
  4. PubMed

    Glutathione and Selenium Supplementation Attenuates Liver Injury in Diethylnitrosamine-Induced Hepatocarcinogenic Mice by Enhancing Glutathione-Related Antioxidant Capacities

    Hsiao YF, Huang SC, Cheng SB, et al. International journal of molecular sciences. 2024

    Source
    Wiki study page →
  5. FDA Drug Label

    WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information

    Novo Nordisk. FDA Drug Label. 2021

    Source
    Wiki study page →
  6. FDA Drug Label

    OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information

    Novo Nordisk. FDA Drug Label. 2017

    Source
    Wiki study page →
  7. PubMed

    Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

    Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Semaglutide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    Once-Weekly Semaglutide in Adolescents with Obesity.

    Weghuber D, Barrett T, Barrientos-Pérez M, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  10. PubMed

    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

    Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. N Engl J Med. 2023

    Source
    Wiki study page →
  11. PubMed

    Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

    Wharton S, Calanna S, Davies M, et al. Diabetes Obes Metab. 2022

    Source
    Wiki study page →
  12. PubMed

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. The New England journal of medicine. 2023

    Source
    Wiki study page →
  13. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  14. PubMed

    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    Wadden TA, Bailey TS, Billings LK, et al. JAMA. 2021

    Source
    Wiki study page →
  15. PubMed

    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    Wilding JPH, Batterham RL, Calanna S, et al. Diabetes Obes Metab. 2022

    Source
    Wiki study page →
  16. PubMed

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6)

    Marso SP, Bain SC, Consoli A, et al. N Engl J Med. 2016

    Source
    Wiki study page →